Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG  by Myint, Theingi et al.
ELSEVIER Biochimica et Biophysica Acta 1272 (1995) 73-79 
Biocht~Pic~a 
et Biophysica A~ta 
Immunological detection of glycated proteins in normal and 
streptozotocin-induced diabetic rats using anti hexitol-lysine IgG 
Theingi Myint, Sakuo Hoshi, Tomomi Ookawara, Nobuko Miyazawa, Keiichiro Suzuki, 
Naoyuki Taniguchi * 
From the Department of Biochemistry, Osaka Unieersity Medical School, 2-2 Yamadaoka, Suita 565, Osaka, Japan 
Received 28 February 1995; accepted 3 April 1995 
Abstract 
A polyclonal antibody specific for the Amadori compound, aproduct of an early stage of the Maillard reaction, was raised in rabbits 
by immunization with hexitol-lysine (l-glucitol-lysine or 1-mannitol-lysine) coupled with various cartier proteins. The affinity purified 
antibody has a high titre and preferentially recognizes the glucose adduct, in the presence of sodium borohydride, as judged on 
enzyme-linked immunosorbent assay as well as immunoblot analysis. The glycated proteins (Amadori products) in various tissues of 
normal and streptozotocin-induced diabetic rats were examined by immunoblot analysis. In diabetic onditions, kidney, liver, lens, brain 
and lung proteins are more susceptible to glycation than other tissue proteins. Heart, spleen, adrenal gland and muscle proteins exhibit 
similar extents of glycation in both normal and diabetic conditions. This is the first demonstration f a specific antibody against he 
Amadori compound being raised with a synthetic ompound, and of the tissue distribution of glycated proteins in normal and diabetic 
conditions. The antibody was very useful for in vitro and in vivo experiments on the Maillard reaction. 
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I. Introduction 
The non-enzymatic glycation, an early stage of the 
Maillard reaction [1 ], is one of the post-translational modi- 
fication processes between free reducing sugars and free 
amino groups or e-amino groups of lysine residues of 
proteins. This reaction is initiated by attachment of the 
aldehyde function of an acyclic sugar to a protein via 
nucleophilic addition, an aldamine, also known as a Schiff 
base, being formed. This intermediate product subse- 
quently undergoes Amadori rearrangement to yield 1- 
amino, 1-deoxy fructose lysine, an early product of the 
Maillard reaction [2,3]. The formation of an Amadori 
product (AP) mostly depends on the degree and duration 
of hyperglycemia, nd the half-lives of proteins in the 
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circulation or tissues [2]. Therefore, these compounds are 
remarkably increased in diabetic and aging persons as 
compared with in euglycemic persons. There have been 
many reports that glycated proteins, such as hemoglobin 
[3], albumin [4], lens crystallins [5] and Cu-Zn SOD [6], 
undergo changes in their structures or functions. Although 
the Amadori compound is relatively stable, it can be 
degraded and cross-linked with other compounds to pro- 
duce a browning product, the advanced glycation end 
(AGE) product of the Maillard reaction [1 ]. The more APs 
are formed, the greater the chance of increased formation 
of AGE products. In contrast o the APs, these adducts, 
once formed are irreversible, and continue to accumulate 
indefinitely on longer-lived proteins. It has been proposed 
that complications in diabetes and aging, such as cataracts, 
atherosclerosis and microvascular diseases, could be partly 
due to glycation process. Measurement of glycated pro- 
teins, like glycated hemoglobin (Hb A Jc) or fructosamine, 
in plasma has been widely used for clinical and laboratory 
purposes [7-11]. Recently, sensitive enzyme-linked im- 
munosorbent assay (ELISA) procedures were developed 
involving monoclonal and polyclonal antibodies raised 
against glycated proteins [12-16]. Some research groups 
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also localized the glycated proteins in skin and kidney by 
means of an immunohistochemical method [17,18]. 
In this paper, we describe a simple method for raising 
an antibody specific to reduced APs, using a protein 
coupled with a synthetic hexitol-lysine compound as an 
immunogen, and demonstrate the nature and extent of 
glycated proteins in various tissue extracts of normal and 
streptozotocin-induced diabetic rats. 
2. Materials and methods 
2.1. Materials and animals 
Glucose, fructose, galactose and glycine were purchased 
from Nacalai Tesque (Kyoto, Japan). Sodium borohydride 
(NaBH4), 4-chloro, 1-naphthol, 1,4-dioxane, and D (+)  
ribose were obtained from Wako Pure Chemical Industries, 
Japan. Keyhole limpet hemocyanin (KLH), ovalbumin 
(OVA), bovine serum albumin (BSA), human serum albu- 
min (HSA), pancreatic ribonuclease (RNase), and o-phen- 
ylenediamine dihydrochloride (OPD-5 mg) were purchased 
from Sigma Chemical. Horseradish peroxidase (HRP)-con- 
jugated goat anti-rabbit IgG was purchased from ZYMED 
Laboratories, San Francisco, CA. Columns of PD-10 
Sephadex G-25 M and activated CH-Sepharose 4B were 
obtained from Pharmacia LKB Biotechnolgy. Polyvinyl- 
idene difluoride (PVDF) transfer membrane (Immobilon) 
was a product of Millipore. The ECL (Enhanced Chemilu- 
minescence) kit used was a product of Amersham Life 
Science, Amersham International, England. Fuji medical 
X-ray film was purchased from Fuji Photo Film. 96-well 
immunoplates were obtained from Nunc. Hexitol-lysine (a 
mixture of glucitol-lysine and mannitol-lysine) was synthe- 
sized according to the method described [19]. Streptozo- 
tocin-induced iabetic rats were obtained by injecting 60 
mg/kg of streptozotocin i to animals via the intravenous 
route, as described [20]. These animals were sacrificed at 
15 weeks after injection. Fasting blood sugar level of 
diabetic rats were 25.7_ 1.15 mmol/1 at the time of 
sacrifice. As a control, the same weeks of non diabetic 
Wistar rats were used. Both control and streptozotocin-in- 
duced diabetic rats were sacrificed under perfusion condi- 
tions and perfused with PBS buffer. 
2.2. Coupling of hexitol-lysine to carrier proteins 
Hexitol-lysine (1 mg) was coupled separately with KLH, 
OVA and BSA. In brief, 10 mg of a carrier protein 
dissolved in 0.5 ml of 10 mM phosphate buffer, pH 6.0, 
and 5 ~1 of glutaraldehyde were incubated for 30 min, 
then 1 mg of hexitol-lysine in 0.5 ml of PBS (pH 7.4), was 
added, and then the mixture was incubated overnight at 
room temperature. After the incubation, the mixture was 
dialyzed against 500 ml of the same PBS for 24 h and then 
used as an immunogen [21]. 
2.3. Production of antiserum and affinity purification of 
the anti hexitol-lysine IgG 
After inoculation into lymph nodes of 100 /zg of either 
hexitol-lysine-KLH, hexitol-lysine-OVA or hexitol-lysine- 
BSA in complete adjuvant, each rabbit received four 
weekly subcutaneous injections of 100 /zg of the same 
antigen. The animals were bled at 7 to 10 days after the 
last injection. Pooled serum was then prepared for purifica- 
tion. The immunoglobulin fraction of rabbit antiserum was 
precipitated with ammonium sulfate. The precipitate was 
dissolved in 10 ml of 50 mM PBS (pH 7.4), and then 
dialyzed against he same buffer for 24 h. 
An affinity column was prepared by coupling of hexi- 
tol-lysine to activated CH-Sepharose 4B according to the 
manufacturer's instructions. The affinity column (1 cm × 7 
cm) was equilibrated with 10 bed voi. of the dialysis 
buffer. The antiserum in PBS was loaded onto the column 
at 30 min intervals, up to 4 ml. Unbound proteins were 
washed out with 7 bed vol. of the starting buffer, and then 
the bound protein was eluted with 7 bed vol. of 100 mM 
glycine-HC1, pH 2.8. The pH of the etuted fractions was 
immediately adjusted to neutral with 2 M Tris buffer. The 
remaining bound proteins were eluted with PBS (pH 7.4), 
containing 10% (v/v)  dioxane. The absorbance of all 
fractions was measured at 280 nm, and peak fractions were 
checked by ELISA on hexitol-lysine-BSA and hexitol- 
lysine-OVA coated immunoplates. The antibody-contain- 
ing fractions were pooled, concentrated and then dialyzed 
against PBS, pH 7.4. 
2.4. Preparation of glycated BSA, HSA and RNase 
Two mg/ml BSA, dissolved in 50 mM PBS (pH 7.4), 
was mixed with 25 mM D (+)  glucose. The mixture was 
sterilized by filtration through a 0.2 /xm Millipore filter 
and then divided into 5 ml samples. Samples were incu- 
bated at 37°C for 0, 1, 3, 5, 7 and 14 days. At the end of 
the incubation times, all the samples were subjected to gel 
filtration on a PD-10 column to remove the excess glucose 
[6]. For the 0-day incubated sample, gel filtration was 
performed immediately after mixing with glucose. For 
control samples, the same concentration f BSA was incu- 
bated at 37°C for 0, 1, 3, 5, 7 and 14 days in the same 
buffer without glucose. Fructated BSA, ribated BSA or 
galactated BSA were obtained by incubation with the 
respective sugar, as described previously [6]. 
Glycated HSA and glycated RNase were prepared by 
incubating 2 mg/ml of each protein and 25 mM D (+)  
glucose at 37°C for 0 to 14 days, as described previously 
[61. 
2.5. Preparation of tissue homogenates and hemolysates 
for Immunoblotting and ELISA 
One part of normal and streptozotocin-induced diabetic 
rat tissues were homogenized in 2 parts of 50 mM PBS 
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(pH 7.4), containing l mM APMSF (p-amidinophenyl, 
methanesulfonyl fluoride hydrochloride), 10 mM benzami- 
dine and 10 /xg of Antipain. The homogenates were 
ultracentrifuged at 100000 × g at 4°C for 1 h. Supernatant 
fractions were obtained and the protein concentration was 
measured with a BCA protein assay reagent kit (Pierce). 
Normal and diabetic rat blood samples were collected in 
tubes in the presence of heparin. Plasma was separated by 
centrifugation. Red blood cells were washed three times 
with a cooled 0.9% sodium chloride solution. A red blood 
cell hemolysate was prepared as described [22]. For hemol- 
ysis, twenty parts of cooled distilled water were added to 
one part of packed red blood cells, followed by vortexing 
in a vortex mixer for 1 min. Then the mixture was allowed 
to stand at room temperature for 5 min. Undissolved 
materials were removed by centrifugation at2000 × g. The 
protein concentration of the supernatant was measured as 
described previously. Then aliquots of supernatants of 
homogenates and hemolysates were subjected to reduction 
for immunoblotting. 
2.6. Reduction of samples with NaBH 4 for immunoblotting 
0.1 M NaBH 4 was prepared in a diluted (0.01 M) 
NaOH solution. A 100 molar excess of the NaBH 4 solu- 
tion was added to samples dissolved in 50 mM PBS, pH 
7.4. The mixtures were incubated at room temperature for 
4 h. The reaction was stopped by adding appropriate 
amounts of concentrated acetic acid to adjust he pH to 5.0 
[2]. Then excess NaBH 4 and acetic acid were removed by 
changing the buffer to 50 mM PBS (pH 7.4), containing 
protease inhibitors, with microconcentrator (Centricon-10. 
Amicon). Protein concentrations were measured again. 
2.7. Immunoblot detection of glycated proteins with a 
polyclonal hexitol-lysine antibody 
This experiment was performed according to the manu- 
facturer's protocol, which is a slight modification of the 
method of Towbin et al. [23]. Reduced, various sugar 
adduct BSA samples were subjected to 10% SDS-PAGE, 
and reduced tissue samples were subjected to 12.5% and 
15% SDS-PAGE. After the electrophoresis, the gels were 
transferred to PVDF membranes under semi-dry conditions 
with the use of a Semi-phor TE-70, a Semi-dry transfer 
unit (Hoefer). We confirmed the transfer of the proteins 
from the gels to the PVDF membranes by staining the gels 
with Coomassie Brilliant Blue R-250. The membranes 
were blocked by incubation with 4% (w/v)  skimmed milk 
in 10 mM Tris-HCl (pH 7.4), containing 0.15 M NaCI 
(TBS), at 37°C for 1 h with gentle agitation. After block- 
ing, the membranes were washed three times with 10 mM 
TBS (pH 7.4) containing 0.1% (w/v)  BSA for 10 min 
each time. Then the membranes were incubated with the 
diluted (1:1000, with the antibody diluent) polyclonal hexi- 
tol-lysine antibody at 4°C overnight. 10 mM TBS (pH 7.4) 
1% (w/v)  BSA containing 0.05% (v/v)  Tween-20 was 
used as the antibody diluent throughout the experiment. 
Then, the membranes were washed with the washing buffer 
and incubated with the second antibody (HRP-conjugated 
goat anti-rabbit IgG diluted to 1:1000 with the antibody 
diluent) for 2 h at room temperature. The second antibody 
solution was decanted and the PVDF membranes were 
washed with the washing buffer. Peroxidase activity (Fig. 
2) was detected in a solution of 4-chloro, 1-naphthol 
containing H20 2 in 10 mM TBS (pH 7.4). The membrane 
was incubated in this solution at room temperature to 
allow the enzyme-substrate reaction to proceed. When the 
desired color intensity was obtained, the reaction was 
stopped by rinsing with distilled water and then the mem- 
brane was dried with paper. For the other membranes (Fig. 
4), the chemiluminescence m thod was used to detect he 
peroxidase activity. After treatment with reagent solutions 
from the ECL kit, the membranes were exposed to the 
X-ray film (Fuji) for an appropriate time. 
2.8. ELISA for determination of glycated proteins in uitro 
and in L'iuo 
Fifty microliter aliquots of various glycated samples, 
appropriately diluted with PBS (pH 7.4), were added to the 
wells of an immunoplate and then incubated for 2 h at 
room temperature. At the same time, samples were re- 
duced by adding 10 /zl of a 0.1 M NaBH 4 solution 
prepared as described above. In the experiment on glycated 
BSA, reduction and non-reduction conditions were used. 
Unbound proteins and excess NaBH 4 solution were re- 
moved by washing four times with PBS containing 0.05% 
(v/v)  Tween-20, and 250 /xl of 1% (w/v)  BSA in PBS 
was added to block the non-specific binding, with incuba- 
tion at room temperature for 2 h. The affinity purified 
polyclonal hexitol-lysine antibody was diluted to 1:1000 
with PBS (pH 7.4). Aliquots, 50 tzl per well, were added 
to the immunoplate, followed by incubation at room tem- 
perature for 2 h. Unbound antibody was removed by 
washing four times with the washing buffer and then 
incubated again with HRP-conjugated goat anti-rabbit IgG 
(1:2000 dilution in PBS, pH 7.4) for 2 h at room tempera- 
ture. Then the unbound second antibody was removed and 
peroxidase activity was detected by adding 50 /zl of a 
OPD solution containing H202, prepared according to 
manufacturer's instruction. The reaction was stopped by 
the addition of 50 /xl of 1 N HzSO 4 to each well. The 
absorbance of each well was determined at 490 nm with an 
Immunoreader NJ 200 (Intermed). 
3. Results 
3.1. Specificity of the polyclonal antibody 
In order to determine the specificity of the polyclonal 
antibody, ELISA analysis of glycated BSA was carried out 
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as described under Section 2, with or without treatment 
with NaBH 4. Non-glycated BSA was used as a control. As 
shown in Fig. 1, the antibody was found to be more 
reactive with a reduced form of glycated BSA, the struc- 
ture of which that of hexitol-lysine, as compared to a 
non-reduced form, 1-amino, 1-deoxyfructose lysine. Non- 
glycated BSA did not react with the antibody. We also 
demonstrated that the antibody recognized both in vitro 
and in vivo glycated proteins, as shown in Fig. 3. Non- 
glycated and glycated HSA, and RNase were used as the 
other in vitro samples, and control and streptozotocin-in- 
duced diabetic rat kidney and lens homogenates, and hu- 
man red cell hemolysates were used as in vivo samples. 
3,2. Relative affinity of the hexitol-lysine antibody ./:or 
various reducing sugar adducts 
The relative affinity of the antibody for various reduc- 
ing sugars, such as galactose, fructose and ribose adducts, 
was determined by immunoblotting (Fig. 2 and Fig. 3). 
The antibody strongly reacted with the AP which had been 
prepared with glucose, but weakly reacted with the APs 
derived from other sugars. 
According to the results in Fig. 1 and Fig. 2, we 
concluded that this antibody is specific to a reduced form 
of AP, an early product of the Maillard reaction, especially 
the glucose adducts. 
3.3. Determination of the nature and extent of the glycated 
proteins in various tissue extracts from normal and strep- 
tozotocin-induced diabetic rats 
Tissue extracts (30 /xg protein) from 4 control and 
steptozotocin-induced diabetic rats were analyzed by im- 
munoblot analysis. Essentially similar patterns on im- 
munoblot analysis were observed. Therefore, typical pat- 
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Fig. 2. Relative affinity of the hexitol-lysine antibody investigated by 
immunoblotting method. 1.25 /zg of each protein was subjected to 10% 
SDS-PAGE. Immunoblot analysis was performed as described under 
Section 2. C, control non-glycated BSA; G, glucated BSA; Gal., galac- 
tated BSA; F, fructated BSA; R, ribated BSA. 
terns were shown in Fig. 4A-D. As shown in Fig. 4A, 
kidney and especially liver proteins were glycated in phys- 
iologic condition, and obviously increased in hyper- 
glycemic ondition (Fig. 4B). In diabetic ondition, glyca- 
tion of lens crystallins was obvious and some immuno- 
reactive bands with high molecular weight were also seen. 
These might represent the cross-linking or aggregation of 
lens crystallins due to the Maillard reaction. Although 
brain, lung, heart, spleen and adrenal gland proteins exhib- 
ited the same susceptibility to glycation in euglycemic 
conditions (Fig. 4A), the brain and lung proteins were 
more prone to glycation than the others in diabetic condi- 
tion (Fig. 4B). The 44 kDa protein in brain tissue was 
physiologically glycated and obvious changes were seen in 
the diabetic ondition. Changes of other proteins, above 44 
kDa, were also seen in the diabetic samples. As can be 
seen in Fig. 4B, other immunoreactive bands in lung alone 
could be blood proteins. However, in the spleen sample, 
which had a greater blood volume than the lung one, there 
were no immunoreactive bands of the same molecular 
weight. Therefore, these immunoreactive materials in lung 
appear to be of lung tissue origin. No apparent changes 
were seen between control and diabetic heart, spleen and 
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Fig. 1. Two mg/ml of BSA was incubated with or without 25 mM 
glucose for the indicated times as described under Section 2. ELISA was 
performed under both reduced and non-reduced conditions. Each value 
indicates the mean value for closely agreeing values of triplicate xperi- 
ments. -0 - ,  reduced glycated BSA; -O- ,  non-reduced glycated BSA; 
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Fig. 3. Reactivity of the hexitol-lysine antibody to in vitro and in vivo 
glycated proteins, as judged by ELISA. Incubated samples and soluble 
fractions of tissue samples were subjected to ELISA. Each value was 
expressed from triplicate experiments. HSA, human serum albumin; 
RNase, pancreatic ribonuclease; r.Kidney, rat kidney homogenate; r.Lens, 
rat lens homogenate; h.Blood, hemolysate of washed human red blood 
cells. II, control or non-glycated sample; m, diabetic or glycated sample. 
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In the immunoblot analysis of pancreas, muscle and 
plasma (Fig. 4C), 2 immunoreactive bands (52 kDa and 40 
kDa) can be seen in control pancreas. In the diabetic 
pancreas, however the 40 kDa band was still remained, the 
52 kDa band was disappeared. New faint bands with 69 
kDa and 28 kDa were also seen in diabetic sample. The 69 
kDa material may be derived from the 52 kDa one, which 
cross-linked with other proteins during the Maillard reac- 
tion. The 28 kDa band may represent a cleaved residue due 
to proteolytic action or a newly formed glycated protein. 
The major muscle proteins, such as myosin (46 kDa), actin 
(43 kDa) and carbonic anhydrase 3 (29 kDa), underwent 
similar glycation in both conditions. Albumin (Fig. 4C) 
and hemoglobin (Fig. 4D) are the major glycated proteins 
in both conditions. Plasma proteins have more chance to 
react with free reducing sugar than other tissue proteins in 
the hyperglycemic stage. Apart from albumin, the other 
serum proteins, including immunoglobulins, were glycated 
in diabetic plasma. Carbonic anhydrases 1 and 2 (29 kDa) 
were more susceptible to the glycation process than other 
blood enzymes (Fig. 4D). In aorta, we cannot conclude 
whether or not all these glycated proteins were of aortic 
origin. Most of the immunoreactive bands such as 67 kDa 
band, 29 kDa band and 16 kDa band, which present in 
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69 kDa "-) 
46 kDa -'-) 
30 kDa 
21.5 kDa --) 
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Diabetic 
c/o o/ 
(-  2oo kDa --) 
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( -  30 kDe --) 
~'-'14.3 kDa -') 
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Fig. 4. Detection ofglycated proteins invarious tissue xtracts ofnormal and streptozotocin-induced diabetic rats. Typical immunoblots fortissue xtracts 
of a control rat (A) and a diabetic rat (B). 30 tzg of each protein was subjected to 12.5% SDS-PAGE. After electrophoresis, immunoblotting was 
performed as described under Section 2. Rainbow-colored protein molecular weight markers (Amersham) was used as standard proteins. Peroxidase 
activity was detected by the ECL method. After treatment with reagents from the ECL kit (Amersham), the membranes were exposed to X-ray film for 5 
sec. Arrowhead, lens crystallins. (C) A typical immunoblot of pancreas, muscle and plasma. Detection was carried out as described under Section 2.30/xg 
of each protein was subjected to12.5% SDS-PAGE. (D) A typical immunoblot of RBC (hemolysate of red blood cell) and aorta. Detection was carried out 
as described under Section 2. 30 /~g of each protein was subjected to 15% SDS-PAGE. 
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aorta, were also seen in plasma (Fig. 4C) and blood (Fig. 
4D), with similar patterns in both conditions. Therefore, 
these bands in aorta sample might be contaminated pro- 
teins from the plasma and/or blood even though tissues 
were extensively perfused. On the other hand, the 42 kDa 
protein was also seen in the plasma of diabetic condition 
(Fig. 4C), the pattern was different from aorta. The inten- 
sity of this band in control aorta was pronounced where as 
no bands were seen in control plasma. Even this band was 
appeared in diabetic plasma, which became faint in dia- 
betic aorta. This suggests that in the aortic origin, an 
advanced changes of the Maillard reaction rather than an 
AP may occur. 
4. Discussion 
Because of the glycated sites are mostly located at 
lysine residues of proteins and the structure of a reduced 
AP comprises mainly 1-deoxy, 1-hexitol-lysine, we used 
this synthetic ompound as an immunogen for the immu- 
nization of rabbits. We purified the antibody by affinity 
chromatography. This antibody is specific to a glucose 
adducts AP, especially to a reduced form and recognizes a
glycated protein produced as a consequences of the Mail- 
lard reaction. Even AGE products, some parts of which are 
produced at an early stage of the Maillard reaction, can 
immunologically react with this antibody [24]. When BSA 
was incubated with fructose, 85% of the free amino groups 
were attached to C2 position, yielding 2-deoxy, 2-amino 
glucose lysine [25]. 1-Deoxy, 1-amino ribose lysine 
residues were produced when BSA was incubated with 
ribose. Hence, these structures were not suitable epitopes 
for this antibody which is specific for l-deoxy, l-hexitol- 
lysine. We can consider the majority of the immuno- 
reactive proteins with this antibody are APs of glucose 
adducts rather than other sugar adducts. 
We demonstrated that a few brain proteins were gly- 
cated in physiological conditions and some brain proteins 
which were not modified by the glycation process in 
normoglycemic condition became glycated in diabetic on- 
dition. Brown et al. reported that brain cytoskeleton pro- 
teins were susceptible to the glycation process in vitro [26]. 
Cytoskeletal proteins of the brain have slow turn over rates 
and have long exposure to ambient blood glucose. There- 
fore, physiologically glycated brain proteins have changed 
into AGE products of the Maillard reaction which may in 
turn cause the senile dementia in aging. Recently, several 
groups proposed that the glycation process may contribute 
to the disease process of Alzheimer's disease [27-29]. 
Among the tissue extracts, even in physiological condition, 
liver proteins were more glycated than others. Permeability 
of glucose into liver cells is independent on insulin. More- 
over, liver cells are always flushed with high glucose level 
via the portal system in postprandial condition as compare 
to others. Takahashi et al. has reported that aldehyde 
reductase of liver from normal rats was partially glycated 
[30]. Proteins of heart, muscle, spleen and adrenal gland 
underwent glycation in both physiologic and diabetic con- 
ditions with similar patterns (Fig. 4A and Fig. 4B). There 
is no report for complications pecific for spleen and 
adrenal gland in diabetic persons or experimental nimals. 
Cardiovascular nd muscular complications may be due to 
a secondary effect of microvascular complications and 
neuropathy [31,32]. As most of the complications in dia- 
betes are manifested in the lens, kidney and vascular 
tissues, we could demonstrate, by using hexitol-lysine 
antibodies, that increased glycated proteins in these tissues. 
But we did not obtain a successful result for the aorta. 
Even though no major complications are manifested in the 
lungs, the glycated proteins were markedly increased in 
diabetes (Fig. 4B). Bren et al. demonstrated that the 
receptor for AGE products (RAGE) is more abundant in 
the lungs than in the liver, kidneys and brain [33]. In the 
blood, apart from hemoglobin, carbonic anhydrase 1 and 2 
underwent glycation in the diabetic condition. Previous 
studies in our laboratory indicated that carbonic anhydrase 
activity was reduced by glycation [34], as in the case of 
Cu-Zn SOD, and this may enhance the acid-base imbal- 
ance in diabetic nephropathy. Glycated Cu-Zn SOD could 
not be detected in this experiment. When Cu-Zn SOD 
undergoes glycation, it is easily attacked by the OH radical 
generated from the Maillard reaction [35]. The damaged 
enzyme is susceptible to proteolysis by macroproteases 
[36]. 
In this study, we could demonstrate the nature and 
extent of glycated proteins in various tissues of normal and 
streptozotocin-induced diabetes rats. This may provide 
some information for understanding the complications in 
aging and diabetes. 
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